Agios Pharmaceuticals Inc (AGIO) Receives $63.74 Average Target Price from Brokerages

Agios Pharmaceuticals Inc (NASDAQ:AGIO) has been assigned an average recommendation of “Buy” from the fifteen research firms that are covering the firm. Four equities research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $63.74.

A number of brokerages have recently weighed in on AGIO. Oppenheimer Holdings Inc. began coverage on Agios Pharmaceuticals in a research report on Tuesday, November 29th. They set a “market perform” rating for the company. Cann began coverage on Agios Pharmaceuticals in a research report on Monday, November 28th. They set a “market perform” rating for the company. Credit Suisse Group AG restated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Monday, November 21st. Canaccord Genuity restated a “buy” rating and set a $90.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, December 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $54.00 price objective (down previously from $60.00) on shares of Agios Pharmaceuticals in a research report on Friday, December 16th.

In related news, CEO David P. Schenkein sold 6,000 shares of the stock in a transaction dated Thursday, February 16th. The shares were sold at an average price of $50.01, for a total value of $300,060.00. Following the completion of the transaction, the chief executive officer now owns 6,000 shares of the company’s stock, valued at approximately $300,060. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Robert Nelsen sold 40,599 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $50.84, for a total transaction of $2,064,053.16. Following the completion of the transaction, the director now directly owns 109,230 shares of the company’s stock, valued at approximately $5,553,253.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 425,045 shares of company stock valued at $21,045,561. 10.55% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its stake in shares of Agios Pharmaceuticals by 20.4% in the third quarter. BNP Paribas Arbitrage SA now owns 14,388 shares of the biopharmaceutical company’s stock valued at $760,000 after buying an additional 2,440 shares during the last quarter. First Mercantile Trust Co. purchased a new stake in shares of Agios Pharmaceuticals during the third quarter valued at about $137,000. Daiwa SB Investments Ltd. purchased a new stake in shares of Agios Pharmaceuticals during the third quarter valued at about $435,000. Parametrica Management Ltd purchased a new stake in shares of Agios Pharmaceuticals during the third quarter valued at about $246,000. Finally, Hamilton Lane Advisors LLC purchased a new stake in shares of Agios Pharmaceuticals during the third quarter valued at about $1,018,000. 88.79% of the stock is owned by hedge funds and other institutional investors.

Your IP Address:

Agios Pharmaceuticals (NASDAQ:AGIO) opened at 56.16 on Thursday. The stock’s market cap is $2.37 billion. The company’s 50-day moving average price is $48.31 and its 200-day moving average price is $49.22. Agios Pharmaceuticals has a one year low of $34.31 and a one year high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 16th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.51) by $0.17. The firm earned $22.65 million during the quarter, compared to analyst estimates of $10.89 million. Agios Pharmaceuticals had a negative return on equity of 53.39% and a negative net margin of 341.56%. The business’s quarterly revenue was up 264.5% compared to the same quarter last year. During the same quarter last year, the business posted ($1.08) earnings per share. Analysts forecast that Agios Pharmaceuticals will post ($7.31) EPS for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

5 Day Chart for NASDAQ:AGIO

Receive News & Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.